Tyra Biosciences, Inc. $TYRA Shares Acquired by Commodore Capital LP

Commodore Capital LP raised its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 8.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 3,375,000 shares of the company’s stock after purchasing an additional 275,000 shares during the quarter. Tyra Biosciences comprises about 2.3% of Commodore Capital LP’s investment portfolio, making the stock its 17th biggest position. Commodore Capital LP owned approximately 0.06% of Tyra Biosciences worth $47,216,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Federated Hermes Inc. boosted its position in shares of Tyra Biosciences by 586.3% during the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after purchasing an additional 1,841 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares during the period. SG Americas Securities LLC acquired a new position in Tyra Biosciences during the third quarter worth $133,000. Russell Investments Group Ltd. boosted its position in shares of Tyra Biosciences by 27.7% during the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after buying an additional 2,766 shares during the period. Finally, Intech Investment Management LLC grew its stake in shares of Tyra Biosciences by 46.5% in the second quarter. Intech Investment Management LLC now owns 19,919 shares of the company’s stock valued at $191,000 after buying an additional 6,322 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Up 0.6%

Shares of Tyra Biosciences stock opened at $36.22 on Friday. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $36.96. The company has a market capitalization of $1.95 billion, a P/E ratio of -18.02 and a beta of 1.06. The company has a 50 day moving average of $31.19 and a 200 day moving average of $22.03.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). As a group, research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TYRA shares. Cantor Fitzgerald assumed coverage on Tyra Biosciences in a report on Tuesday, February 24th. They set an “overweight” rating for the company. Wall Street Zen lowered shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. William Blair assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, February 10th. They set an “outperform” rating on the stock. Barclays began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, Jefferies Financial Group upped their price objective on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.33.

Insider Transactions at Tyra Biosciences

In other news, Director Robert J. More sold 10,000 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director directly owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. This represents a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.20% of the stock is owned by company insiders.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.